After Oppenheimer and H.C. Wainwright gave Vascular Biogenics (NASDAQ: VBLT) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Geulah Livshits reiterated a Buy rating on Vascular Biogenics today and set a price target of $5.00. The company’s shares closed last Thursday at $2.55.
According to TipRanks.com, Livshits is a top 100 analyst with an average return of 67.6% and a 66.7% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics, and Adverum Biotechnologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vascular Biogenics with a $5.00 average price target.
See today’s analyst top recommended stocks >>
Based on Vascular Biogenics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $185K and GAAP net loss of $6.28 million. In comparison, last year the company earned revenue of $366K and had a GAAP net loss of $5.35 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi’in, Israel.
Read More on VBLT:
